US Market Report for Atrial and Ventricular Septal Defect Devices 2018 - MedCore

  • ID: 4435263
  • Report
  • Region: United States
  • 384 pages
  • iData Research
15 % OFF
until Oct 31st 2018
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Boston Scientific
  • Cryolife
  • Karl Storz
  • Microline Surgical
  • SentreHeart
  • MORE
VSDs are defects in the ventricular septum, the wall dividing the left and right ventricles of the heart. VSDs are similar to ASDs but tend to cause fewer complications because VSDs are small and most people with the defect barely feel the symptoms. However, approximately 10% of individuals with VSD will develop Eisenmenger’s Syndrome, which is a condition that can curtail life expectancy by several years.

This condition can also be found in ASD patients. VSDs are found in approximately 3 to 3.5 of every 1,000 births but the vast majority of VSDs are likely to close spontaneously during childhood. Only in a small percentage of cases, they will have to be treated surgically. ASDs and VSDs can be treated percutaneously by inserting a device through the defect, which expands and forms a seal around the defect. Many of these devices allow heart tissue to grow over the device with time.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Boston Scientific
  • Cryolife
  • Karl Storz
  • Microline Surgical
  • SentreHeart
  • MORE
EXECUTIVE SUMMARY
U.S. CARDIAC SURGERY AND HEART VALVE DEVICE MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE NUMBERS
PROCEDURE CODES INVESTIGATED
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY

1. RESEARCH METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecasts and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring

2. DISEASE OVERVIEW
2.1 BASIC ANATOMY
2.1.11 Coronary Artery Disease
2.1.12 Myocardial Infarction
2.1.13 Angina Pectoris
2.1.14 Heart Valve Disease
2.1.15 Congestive Heart Failure

3. PRODUCT PORTFOLIO
3.1.1 Tissue Heart Valves
3.1.2 Mechanical Tissue Heart Valves
3.1.3 Annuloplasty Repair Devices
3.1.4 Transcatheter Aortic Valve Replacement Devices
3.1.5 Transcatheter Mitral Valve Repair Devices
3.1.6 On-Pump Coronary Artery Bypass Devices
3.1.7 Off-Pump Coronary Artery Bypass Devices
3.1.8 Endoscopic Vessel Harvesting Devices
3.1.9 Anastomosis Assist Devices
3.1.10 Transmyocardial Revascularization Devices
3.1.11 Ventricular Assist Devices
3.1.12 Intra-Aortic Balloon Pump Device
3.1.13 Temporary Artificial Heart Replacement Device
3.1.14 Remote Hemodynamic Monitoring System Devices
3.1.15 Patent Foramen Ovale Devices
3.1.16 Atrial & Ventricular Septal Defect Device
3.1.17 Left Atrial Appendage Closure Device
3.1.18 Extracorporeal Membrane Oxygenation Machine
3.2 FDA RECALLS
3.2.1 MAQUET
3.2.2 Medtronic
3.2.3 HeartWare Inc
3.3 CLINICAL TRIALS
3.3.1 Medtronic
3.3.2 St. Jude Medical
3.3.3 Abiomed
3.3.4 Heartware Inc

4. ATRIAL AND VENTRICULAR SEPTAL DEFECT DEVICE MARKET
4.1 INTRODUCTION
4.2 MARKET OVERVIEW
4.3 MARKET ANALYSIS AND FORECAST
4.3.1 Total Atrial and Ventricular Septal Defect Device Market
4.3.2 Atrial Septal Defect Device Market
4.3.3 Ventricular Septal Defect Device Market
4.4 DRIVERS AND LIMITERS
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 COMPETITIVE MARKET SHARE ANALYSIS

ABBREVIATIONS

APPENDIX: COMPANY PRESS RELEASES

List of Charts
Chart 1 1: Cardiac Surgery and Heart Valve Devices Market by Segment, U.S., 2014 – 2024
Chart 1 2: Cardiac Surgery and Heart Valve Devices Market Overview, U.S., 2017 & 2024
Chart 4 1: Atrial and Ventricular Septal Defect Device Market by Segment, U.S., 2014 – 2024
Chart 4 2: Atrial and Ventricular Septal Defect Device Market Breakdown by Segment, U.S., 2017
Chart 4 3: Atrial and Ventricular Septal Defect Device Market Breakdown by Segment, U.S., 2024
Chart 4 4: Total Atrial and Ventricular Septal Defect Device Market, U.S., 2014 – 2024
Chart 4 5: Atrial Septal Defect Device Market, U.S., 2014 – 2024
Chart 4 6: Ventricular Septal Defect Device Market, U.S., 2014 – 2024
Chart 4 7: Leading Competitors, Atrial and Ventricular Septal Defect Device Market, U.S., 2017

List of Figures:
Figure 1 1: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (1 of 4)
Figure 1 2: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (2 of 4)
Figure 1 3: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (3 of 4)
Figure 1 4: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (4 of 4)
Figure 1 5: Companies Researched in this Report, U.S., 2017
Figure 1 6: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (1 of 4)
Figure 1 7: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (2 of 4)
Figure 1 8: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (3 of 4)
Figure 1 9: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (4 of 4)
Figure 1 10: Recent Events in the Cardiac Surgery and Heart Valve Devices Market, U.S., 2015 – 2017
Figure 1 11: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (1 of 4)
Figure 1 12: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (2 of 4)
Figure 1 13: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (3 of 4)
Figure 1 14: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (4 of 4)
Figure 1 15: Procedure Codes Investigated, U.S., 2017
Figure 1 16: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (1 of 2)
Figure 1 17: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (2 of 2)
Figure 1 18: Key Report Updates (1 of 2)
Figure 1 19: Key Report Updates (2 of 2)
Figure 1 20: Version History
Figure 3 1: Tissue Heart Valves by Company
Figure 3 2: Mechanical Tissue Heart Valves by Company
Figure 3 3: Annuloplasty Repair Devices by Company
Figure 3 4: Transcatheter Heart Valve Replacement Devices by Company
Figure 3 5: Transcatheter Mitral Valve Repair Devices by Company
Figure 3 6: On-Pump Coronary Artery Bypass Devices by Company
Figure 3 7: Off-Pump Coronary Artery Bypass Devices by Company
Figure 3 8: Endoscopic Vessel Harvesting Devices by Company
Figure 3 9: Anastomosis Assist Devices by Company
Figure 3 10: Transmyocardial Revascularization Devices by Company
Figure 3 11: Ventricular Assist Devices by Company
Figure 3 12: Intra-Aortic Balloon Devices by Company
Figure 3 13: Temporary Artificial Heart Replacement Devices by Company
Figure 3 14: Remote Hemodynamic Monitoring System Devices by Company
Figure 3 15: Patent Foramen Ovale Devices by Company
Figure 3 16: Atrial & Ventricular Septal Defect Devices by Company
Figure 3 17: Left Atrial Appendage Closure Devices by Company
Figure 3 18: Extracorporeal Membrane Oxygenation Machine by Company
Figure 3 19: Class 2 Device Recall MAQUET
Figure 3 20: Class 2 Device Recall MAQUET
Figure 3 21: Class 2 Device Recall MAQUET
Figure 3 22: Class 1 Device Recall Medtronic
Figure 3 23: Class 1 Device Recall Heartware Inc
Figure 3 24: The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
Figure 3 25: Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance
Figure 3 26: Medtronic CoreValve Evolut R U.S. Clinical Study
Figure 3 27: Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients
Figure 3 28: AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption
Figure 3 29: AMPLATZER Duct Occluder II Additional Sizes (ADO II AS)
Figure 3 30: HeartMate 3 CE Mark Study Long Term Follow-up (HM3 CE LTFU)
Figure 3 31: Trifecta™ GT Post Market Clinical Follow-up
Figure 3 32: AMPLATZER™ LAA Occluder Post Approval Study (PAS)
Figure 3 33: AMPLATZER™ Cardiac Plug Observational Post-Approval Study (ACP PAS China)
Figure 3 34: MOMENTUM 3 Continued Access Protocol (MOMENTUM 3 CAP)
Figure 3 35: AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE)
Figure 3 36: Prevention of Non-Surgical Bleeding by Management of HeartMate II
Figure 3 37: Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction (DTU)
Figure 3 38: Protected PCI Study
Figure 3 39: Assessment of the WATCHMAN™ Device
Figure 3 40: Watchman FLX Left Atrial Appendage Closure Device Post Approval Study
Figure 3 41: Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
Figure 4 1: Atrial and Ventricular Septal Defect Device Market by Segment, U.S., 2014 – 2024 (US$M)
Figure 4 2: Total Atrial and Ventricular Septal Defect Device Market, U.S., 2014 – 2024
Figure 4 3: Atrial Septal Defect Device Market, U.S., 2014 – 2024
Figure 4 4: Ventricular Septal Defect Device Market, U.S., 2014 – 2024
Figure 4 5: Drivers and Limiters, Atrial and Ventricular Septal Defect Device Market, U.S., 2017
Figure 4 6: Leading Competitors, Atrial and Ventricular Septal Defect Device Market, U.S., 2017
Figure 6 1: Press Release Summary
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Edwards Lifesciences
  • St. Jude Medical
  • Medtronic
  • Maquet
  • Abiomed
  • HeartWare Inc.
  • Sorin Group
  • Terumo
  • Abbott Laboratories
  • Teleflex Medical
  • Cardiac Assist
  • AtriCure
  • W.L. Gore
  • SynCardia
  • Boston Scientific
  • Cryolife
  • Berlin Heart
  • Cardica
  • Chase Medical
  • Genesee Biomedical
  • Karl Storz
  • LifeNet Health
  • Microline Surgical
  • Novadaq
  • On-X
  • Saphena Medical
  • SentreHeart
  • Vitalitec
Please Note: Not all companies are currently active in every segment or sub-report from this suite.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll